文献速递白血病

KIT突变对RUNX1-RUNX1T1与CBFB-MYH11急性髓系白血病预后影响的前瞻性评估

Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
PubMed 文献 · Blood Adv · 2020-01-01

本研究前瞻性纳入199例16-64岁初诊CBF-AML完全缓解患者,接受3疗程大剂量阿糖胞苷治疗后随访。建议对两亚型分别评估预后因素。

要点

  • KIT突变提示CBF-AML患者RFS较差,但预后影响仅见于RUNX1-RUNX1T1亚型。
  • 仅KIT外显子17突变对RUNX1-RUNX1T1患者RFS有显著不良影响。
  • CBFB-MYH11患者中MRD与较差RFS相关,而RUNX1-RUNX1T1中未见此关联。

核心结论

  • KIT突变对CBF-AML的预后影响因融合基因亚型而异,应分别评估RUNX1-RUNX1T1与CBFB-MYH11的预后因素。

研究设计与样本

  • 前瞻性注册研究,纳入199例16-64岁初诊de novo CBF-AML且达完全缓解的患者,接受3疗程大剂量阿糖胞苷治疗。
  • 分析KIT外显子8、10-11、17突变及56个髓系恶性肿瘤常见基因突变,并评估112例患者的MRD。
  • 主要终点为按KIT突变状态分组的无复发生存(RFS)。

主要发现

  • 亚组分析显示KIT突变仅对RUNX1-RUNX1T1患者有预后影响,对CBFB-MYH11患者无影响。
  • 仅KIT外显子17突变对RFS有显著预后影响。
  • 多因素Cox回归显示RUNX1-RUNX1T1患者中KIT外显子17突变和髓外肿瘤为RFS不良因素。
  • CBFB-MYH11患者中染色体X或Y缺失及NRAS突变为RFS不良因素。

临床怎么用

  • 对CBF-AML患者应常规检测KIT突变,并区分融合基因亚型解读其预后意义。
  • RUNX1-RUNX1T1患者伴KIT外显子17突变或髓外肿瘤提示RFS较差,需加强监测。
  • CBFB-MYH11患者应关注MRD、染色体X或Y缺失及NRAS突变以评估复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prognostic impact of KIT mutation on core-binding factor acute myeloid leukemia (CBF-AML) remains controversial. We registered 199 newly diagnosed de novo CBF-AML patients, aged 16 to 64 years, who achieved complete remission. They received 3 courses of high-dose cytarabine therapy and no further treatment until hematological relapse. Mutations in exons 8, 10-11, and 17 of the KIT gene were analyzed. Furthermore, we analyzed mutations in 56 genes that are frequently identified in myeloid malignancies and evaluated minimal residual disease (MRD). The primary end point was relapse-free survival (RFS) according to KIT mutations. The RFS in KIT-mutated patients was inferior to that in unmutated patients (hazard ratio, 1.92; 95% confidence interval, 1.23-3.00; P = .003). Based on subgroup analysis, KIT mutations had a prognostic impact in patients with RUNX1-RUNX1T1, but not in those with CBFB-MYH11, and only exon 17 mutation had a significant prognostic impact. Multivariate Cox regression analysis with stepwise selection revealed that the KIT exon 17 mutation and the presence of extramedullary tumors in patients with RUNX1-RUNX1T1, and loss of chromosome X or Y and NRAS mutation in patients with CBFB-MYH11 were poor prognostic factors for RFS. MRD was evaluated in 112 patients, and it was associated with a poorer RFS in the patients with CBFB-MYH11, but not in those with RUNX1-RUNX1T1. These results suggested that it is necessary to separately evaluate AML with RUNX1-RUNX1T1 or CBFB-MYH11 according to appropriate prognostic factors. This study was registered at www.umin.ac.jp/ctr/ as #UMIN000003434.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ishikawa Y, Kawashima N, Atsuta Y, et al. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Blood Adv. 2020. PMID: 31899799. doi:10.1182/bloodadvances.2019000709

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。